Belle Health Review

What Belle Health charges

• NAD+: $149/mo — from, per month on the 3-month supply; the same pricing page publishes $199/month on the 1-month supply
• Sermorelin: $119/mo — from, per month; the pricing page publishes this figure only on a 3-month supply and lists no 1-month option
• Glutathione: $119/mo — from, per month; the pricing page publishes this figure on a 2-month supply and lists no 1-month option

Four pharmacies, named — and two lists that disagree

The FAQ answer names four US-licensed compounding and dispensing pharmacies by name, and says prescriptions route to whichever is best positioned to fill a given medication.

The pricing page goes further and tags each product card with the pharmacy behind it, so the three tracked compounds carry two names between them.

Those two disclosures are not the same list: one name appears on the cards but not in the FAQ, and two appear in the FAQ but not on the longevity cards.

Both readings are in the record rather than reconciled into a tidier one, because both are published by this seller on the same day.

The same figure on two surfaces, which is rarer than it sounds

Each of the three tracked compounds has a product page carrying a per-month figure, and a pricing-table row carrying the same one.

The pricing table adds the supply term each figure is attached to, and those terms are not identical across the three.

One compound also has a shorter, dearer option listed beside the headline one; the other two do not.

A figure that survives being printed twice, in two layouts, is a small signal that somebody is maintaining it.

The copper-peptide products are priced but not purchasable

Two skin products built on a tracked compound appear in the pricing table with figures attached.

The control on each reads Coming Soon rather than the button every other product carries.

So the compound is not recorded as one this seller sells, even though a figure sits next to it.

A price beside a disabled control is an announcement, and reading it as availability is how a comparison ends up sending someone to a page they cannot buy from.

What is not established here

No state list is published anywhere on the pages read, so eligibility is settled inside the intake rather than before one.

Lab work is described as ordered only when a clinician judges it necessary, and never as included in the published price.

The federal warning-letter record returned one entry against this seller's operating company, issued in February 2026, and its stated subject is marketing claims.

The letter URL was fetched and resolved in the same run in which a nonsense letter path on the same federal host returned a 404, so its existence rests on a page, not on a status code.

FDA disclosure

Belle Health received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.

How we verified this

• Rendered every page cited on this row in a real browser engine and read the laid-out text nodes, so nothing here rests on markup that never reaches a reader.
• Fired two nonsense-path controls at this host in the same run — one at the root and one inside the section the priced pages live in — and compared the address requested with the address actually served.
• Joined every text node before scanning for a dollar sign, so a figure split across nested elements could not read as an absence.
• Screened this seller in the live federal warning-letter record by brand and, where an operating company is published, by entity — pulling the whole table and filtering locally, because that endpoint's own search parameter is silently ignored.
• Ran a known-good positive control and a nonsense negative control against that table in the same run, and read the company column of every returned record rather than accepting a full-text match.
• Clicked the FAQ accordion open before reading it, because the pharmacy answer and the lab answer are both absent from the collapsed page text and a sweep of that text alone would have recorded them as unpublished.
• Read the pricing page's per-product pharmacy tags separately from the FAQ list, and recorded the difference between them rather than merging the two.
• Checked the control on each copper-peptide product before treating its figure as an offer, and found it reads Coming Soon.
• Fetched the warning-letter page itself and, in the same run, a nonsense letter path on the same federal host, which returned a 404.